Industry

DUBLIN–(BUSINESS WIRE)–The “Blood Glucose Meters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information about the Blood Glucose Meters pipeline products with comparative analysis of the products at various stages of development and information about … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Heart Lung Machine Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering. This report on the global heart lung machine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market … [Read more…]

DUBLIN–(BUSINESS WIRE)–Terebellum, subsidiary of AscellaHealth, a global specialty pharmacy and healthcare solutions organisation, has announced the appointment of two executive positions to drive its growth in the UK and EU. A Vice President of Market Access & Commercialisation and a dedicated Regional Director join Ireland and UK-based Terebellum as it expands its international footprint to … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Medical Device Security Market 2021-2031: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. The global medical device security market will reach $ 18,526.3 million by 2031, growing by 11.2% annually over 2021-2031, driven by the growing demand for connected medical devices due to the aging population and the … [Read more…]

Mursla adds seasoned executive with a wealth of experience in rapid growth and product commercialisation to leadership team CAMBRIDGE, England–(BUSINESS WIRE)–#Cambridge–Mursla, a novel multi-omics exosome characterisation company, is delighted to announce the appointment of Karin Schmitt, PhD as Chief Operating Officer. A highly respected life science executive, Karin has almost three decades of international experience … [Read more…]

RIYADH, Kingdom of Saudi Arabia–(BUSINESS WIRE)–#genomics–King Faisal Specialist Hospital and Research Centre (KFSH&RC) will integrate Saphetor’s proprietary human genome variant interpretation engine, VarSome, into its research and clinical genomics programs. The integration aligns with Saudi Arabia’s Vision 2030 to strengthen the Kingdom’s healthcare sector and its services with technological advancements. KFSH&RC is a leading tertiary … [Read more…]

Company Also Appoints Seasoned Industry Executive, Dr. Angelos Stergiou, as Board of Directors Chairman in Advance of Lead Program Entering the Clinic UTRECHT, Netherlands–(BUSINESS WIRE)–CLEARA Biotech B.V. (“Cleara” or the “Company”), a preclinical-stage biotechnology company focused on developing innovative, proprietary therapies for treating different pathologies of “scarred cellular” senescence, including late-stage cancer and chronic diseases, … [Read more…]

Replacing Makis Kosmatos, Raghu Krishnan will spearhead all areas of Johnson & Johnson’s Consumer health strategic development across the area DUBAI–(BUSINESS WIRE)–Johnson & Johnson Consumer Health, are pleased to announce the appointment of Raghu Krishnan as the new Area Managing Director for AMET (Africa, Middle East, and Turkey), effective September 1st, 2022. Raghu Krishnan is … [Read more…]

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced that it has entered into a Commitment Letter with certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), pursuant to which Highbridge has committed to provide a … [Read more…]

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced the pricing of a follow-on public offering of 12,905,000 of its ordinary shares at a public offering price of $1.55 per share for aggregate gross proceeds … [Read more…]